ContraFect Presents New CF-301 Data at ASM Microbe 2016

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ContraFect Presents New CF-301 Data at ASM Microbe 2016

YONKERS, NY --(Marketwired - June 21, 2016) - ContraFect Corporation ( NASDAQ : CFRX ) ( NASDAQ : CFRXW ) , a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today provides details of new data presented at the ASM Microbe 2016 Conference (ASM 2016), which was held June 16-20, 2016 in Boston, MA.

ContraFect scientists presented new data at ASM 2016, which advance the understanding of the projected efficacious human dose and microbiologic profile of CF-301, which is currently in development for the treatment of Staphylococcus aureus ( Staph aureus ) bloodstream infections, including MRSA. Presentations included a Late Breaker poster presentation on the pharmacokinetics-pharmacodynamics (PK-PD) drivers of efficacy of CF-301, and two oral presentations of new microbiologic data: one showing the lack of CF-301 resistance development among Staph aureus strains exposed to CF-301, and the other describing the post-antibiotic effect of CF-301.

Late Breaker Poster Presentation: "PK-PD Driver of Efficacy for CF-301, a Novel Anti-Staphylococcal Lysin: Implications for Human Target Dose"

Key Points

  • PK-PD modeling of data from animal models and human clinical studies is a well-established methodology to determine the target human blood levels and human dosing of antibacterial agents.
  • Standard mouse infection model studies to determine the optimal dosing regimen of CF-301 for maximal bacterial killing were conducted using ten strains of Staph aureus isolated from human infections. Additional experiments using CF-301 in combination with antibiotics were also performed.
  • Target efficacious blood levels were determined from these animal studies and combined with human population PK analyses conducted using blood levels of CF-301 measured in the Phase 1 study of CF-301 (to be presented elsewhere) to determine the doses of CF-301 expected to be efficacious in humans.
  • Human doses of ≥0.25 mg/kg were projected to exceed the target level required for maximal killing when combined with standard of care agents, supporting the choice of a 0.25 mg/kg dose which has been selected for use in an upcoming Phase 2 clinical trial.

Oral Presentation: "Staphylococcus aureus Resistance to Lysin CF-301 Does Not Arise in Human Serum"

Key Points

  • Serial passage studies are a standard method to determine the propensity of bacteria to form resistance to an antibiotic agent.
  • CF-301 was studied in serial passage studies in human serum using Staph aureus strains over a period of 21-26 days, showing that high levels of resistance to CF-301 do not emerge in human serum.
  • While exposure of MRSA to CF-301 in the serial passage assays did not result in CF-301 resistance, it did, however, result in increased sensitivity to oxacillin (with corresponding MIC decreases of 16 to 32 fold).

Oral Presentation: "Post-Antibiotic Effects of Lysin CF-301 Against Staphylococcus aureus"

Key Points

  • A post-antibiotic effect (PAE) is a prolonged biologic effect seen after drug levels decline to zero, and may convey additional therapeutic benefit to infected patients beyond the period of drug exposure.
  • The PAE of CF-301 was studied in vitro using 14 different Staph aureus strains from human infections both as a monotherapy and in combination with daptomycin. CF-301 was further studied in a model of biofilm formation and a mouse model of infection.
  • After exposure to, and removal of CF-301, bacterial growth was suppressed in the in vitro growth, biofilm formation, and mouse infection model, with strong PAEs in all three systems.
  • Additional in vitro growth PAE experiments examining combinations of CF-301 with daptomycin indicate synergistic PAE enhancement for the combination, adding to the rationale for combination dosing in the upcoming CF-301 Phase 2 trial.

About CF-301

CF-301 is a recombinant bacteriophage-derived lysin with potent bactericidal activity against Staph aureus , a major cause of blood stream infections, or bacteremia. CF-301 has the potential to be a first-in-class treatment for Staph aureus bacteremia. It has a novel, rapid, and specific mechanism of bactericidal action against Staph aureus and does not impact the body's natural bacterial flora. By targeting a conserved region of the cell wall that is vital to bacteria, resistance is less likely to develop to CF-301. Combinations of CF-301 with standard of care antibiotics significantly increased bacterial killing and survival in animal models of disease when compared to treatment with antibiotics or CF-301 alone. In addition, in vitro and in vivo experiments have shown that CF-301 is highly active against biofilm formation. CF-301 was licensed from The Rockefeller University and is being developed at ContraFect.

About ContraFect:

ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). ContraFect's initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (Methicillin-resistant Staph aureus) and influenza.

FORWARD-LOOKING STATEMENTS

This press release contains, and our officers and representatives may make from time to time, "forward-looking statements" within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar references to future periods. Examples of forward-looking statements include statements made regarding ContraFect's therapeutic product candidate CF-301, including its ability to: treat Staph aureus infections, including MRSA, show lack of resistance development, convey a post-antibiotic effect, be a first-in-class treatment, show increased effectiveness when combined with other antibiotics and show activity against biofilm formation; CF-301 Phase 2 study plans, including dose amount and combination dosing; and in vitro and in vivo study results. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect's current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect's control, including those detailed in ContraFect's filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, among others, our ability to develop treatments for drug-resistant infectious diseases. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Relations Contact Paul Boni ContraFect Corporation Tel: 914-207-2300 Email: pboni@contrafect.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 210

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 49

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 360

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 64

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
HONOR Leads in China, Eyes Middle East Market

Updated Category News Views 0

A Force to be Reckoned With Talk about making waves—HONOR's got the bragging rights now. Sitting pretty at the top among Android smartphone brands in China ain't no small feat. We're looking at a snazzy 12.04% market share for October 2026, all thanks to selling a cool 2.573 million units. The kicker? This ain't even their full potential. They're hustling hard in the...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 349

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 98

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 16

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 138

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 548

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading

Top 5 Most Recently Viewed Articles

Key Insights on Paragon 28, Inc. Class Action Lawsuit

Updated Category News Views 106

Understanding the Paragon 28 Class Action Lawsuit Recently, investors in Paragon 28, Inc. have been alerted about a significant class action lawsuit involving the company's financial disclosures. The litigation revolves around potential inaccuracies in previously issued financial statements. Investors must be aware that the upcoming deadline to file a lead plaintiff...

Continue Reading
Newtopia Partners with Payvider for Enhanced Health Benefits

Updated Category News Views 278

Newtopia Partners with Payvider for Enhanced Health Benefits Newtopia Inc. (NEWU; NEWUF), a leader in tech-enabled habit change solutions, is thrilled to announce its new partnership with a supplemental insurance payvider. This exciting collaboration aims to provide Newtopia's successful habit change platform as a fully-covered benefit for thousands of workers in the...

Continue Reading
A4A Celebrates 250 Years of American Independence through Aviation

Updated Category News Views 94

A4A Launches Campaign for America's 250th Anniversary Airlines for America (A4A) is excited to unveil a memorable campaign, "Red, Flight & Blue—Celebrating America 250," which aims to celebrate the 250th anniversary of the United States. This significant campaign will utilize a variety of platforms, including social media, blog posts, and videos, to highlight the...

Continue Reading
Alexander’s Secures $400M Loan for New York Office Refinancing

Updated Category News Views 238

ALEXANDER’S, INC. concluded a hefty refinancing deal worth $400 million for its office condominium at 731 Lexington Avenue back in 2024. This isn’t just any property; it’s where Bloomberg LP hangs its hat—a landmark in the bustling New York City real estate scene. Traders were glued to this one because it wasn’t just about refinancing but about what it signals...

Continue Reading
IDV Secures Major Contract for Military Logistics Vehicles

Updated Category News Views 239

IDV Secures a Major Tender from the Dutch Armed Forces In a significant development for military logistics, IDV, part of the renowned Iveco Group (EXM: IVG), has successfully secured a contract with the Dutch Ministry of Defence. This contract entails supplying an impressive fleet of 785 military logistics vehicles, which includes three distinct versions: semitrailer...

Continue Reading